Loading...
OTCM
VIRX
Market cap388kUSD
Jul 16, Last price  
0.01USD
Name

Viracta Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:VIRX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
106.99%
Rev. gr., 5y
-7.52%
Revenues
0k
10,304,98916,521,85013,709,1869,663,5135,417,3403,761,54733,0835,000,0003,754,0007,956,0005,734,0003,061,0002,536,000669,000237,0002,073,000120,000000
Net income
-51m
L+2.58%
-20,530,200-27,488,933-31,230,388-40,317,086-37,356,935-63,238,979-24,587,485-20,441,000-45,806,000-37,515,000-44,721,000-36,676,000-38,023,000-35,458,000-26,615,000-23,330,000-19,199,000-203,062,000-49,774,000-51,058,000
CFO
-40m
L+12.51%
-10,410,216-20,945,737-27,084,635-34,455,646-35,460,959-20,183,029-19,379,421-22,836,000-10,642,000-37,423,000-43,181,000-38,731,000-36,962,000-36,142,000-24,404,000-22,185,000-16,054,000-18,851,000-35,457,000-39,892,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Viracta Therapeutics, Inc. operates as a precision oncology firm, specializing in the development of therapeutic agents aimed at treating cancers linked to viral infections. The company's leading drug candidate, Nana-val (a combination of nanatinostat and valganciclovir), is currently advancing through multiple clinical trials. It is in Phase II development for Epstein-Barr virus-positive (EBV+) lymphoma. Furthermore, Nana-val is being evaluated in an open-label Phase 2 basket trial, which targets various forms of relapsed/refractory EBV+ lymphoma, and an open-label Phase 1b/2 trial for EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Beyond its flagship program, Viracta's pipeline features vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor, and VRx-510 (previously known as SNS-510), a PDK-1 inhibitor in its preclinical phase. The company is actively exploring opportunities for development and potential collaborations, particularly for vecabrutinib in conjunction with chimeric antigen receptor (CAR) T-cell therapies, and for VRx-510 across diverse oncological indications. Established in 1998, the company changed its name from Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. on February 25, 2021. Its corporate headquarters are located in Cardiff-by-the-Sea, California.
URL
https://www.viracta.com/
IPO date
Sep 27, 2005
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT